FindTrial
Sign In

A Phase 1b/2 Study of MEDI4736 in Combination With tremelimumab, MEDI4736 Monotherapy, and tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 1b/2 Study of MEDI4736 in Combination With tremelimumab, MEDI4736 Monotherapy, and tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223020
Enrollment
6
Registered
2015-11-19
Start date
2015-11-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

investigational material(s) Generic name etc : MEDI4736, tremelimumab INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investiga

Sponsors

AstraZeneca
Lead Sponsor
MedImmune LLC
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female subjects 2. 18 years and older 3. Histological or cytological confirmation of metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma 4. Subjects must have received and have progressed, or are refractory to standard regimens 5. Subjects must have at least one lesion amenable to biospy

Exclusion criteria

Exclusion criteria: 1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment 2. Previous immunotherapy 3. Concurrent or prior use of immunosuppressive medication with 14 days 4. Active or prior documented autoimmune or inflammatory disease within 3 years with some exceptions

Design outcomes

Primary

MeasureTime frame
safety -—

Secondary

MeasureTime frame
safety efficacy -—

Countries

Asia except Japan, Japan, North America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026